177Lu-PSMA raDioligand therapy for prostate cancer

Wolfgang P. Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, Matthias Eiber

Research output: Contribution to journalArticlepeer-review

144 Scopus citations


177Lu-prostate-specific membrane antigen (PSMA) raDioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients withmetastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, incluDing patient stratification, the therapy protocol, concomitant meDication, and follow-up, to inform meDical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)1196-1200
Number of pages5
JournalJournal of Nuclear Medicine
Issue number8
StatePublished - 1 Aug 2017
Externally publishedYes


  • Education
  • Genitourinary
  • Lutetium
  • PSMA
  • RaDionuclide therapy
  • Therapy


Dive into the research topics of '177Lu-PSMA raDioligand therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this